Trial of EXenatide in Acute Ischaemic Stroke

Phase 2

Completed

• Conditions: acute ischaemic stroke; Stroke - Ischaemic

• Registration Number: ACTRN12617000409370
• Lead Sponsor: Monash University Eastern Health Clinical School.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-03-21
• Study Completion: 2022-03-10
• Last Update Posted: 17 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

Males and females 18 years or older
Acute Ischaemic stroke – (CT to exclude haemorrhagic stroke)
Blood sugar level on admission greater than or equal to 4mmol/L
First trial treatment possible within 9 hours of stroke onset
Pre-morbid mRS score of 0-2

Exclusion Criteria

Haemorrhagic stroke
Poor clinical prognosis /palliation. (considered unlikely to survive beyond 14 days post stroke)
Any known allergy or hypersensitivity to Exenatide
Females who are pregnant (known or suspected) or currently breastfeeding
Any past history of pancreatitis or evidence of active pancreatitis
Past history of severe gastrointestinal disease (including but not limited to gastroparesis and dumping syndrome)
*Current chronic kidney disease stage 4 or 5 (creatinine clearance <30ml/min)
*Current participation in another investigational drug or interventional trial.
*Inability to provide consent (participant or person responsible as local laws apply)

Study & Design

• Study Type: Interventional
• Study Design: Not specified